The impact of diabetes mellitus on outcome of patients undergoing transcatheter aortic valve replacement

Sa'ar Minha, Marco A. Magalhaes, Israel M. Barbash, Itsik Ben-Dor, Ricardo O. Escarcega, Petros G. Okubagzi, Nevin C. Baker, Fang Chen, Rebecca Torguson, William O. Suddath, Lowell F. Satler, Augusto D. Pichard, Ron Waksman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The outcomes of patients with diabetes mellitus (DM) who are referred to surgical aortic valve replacement are poor in comparison to non-diabetic (ND) patients. However, the outcome of diabetic patients referred to transcatheter aortic valve replacement (TAVR) is less established. Further, DM and AS are both associated with left ventricular hypertrophy. It is not clear if alleviation of AS results in greater degree of reverse remodeling in DM patients in comparison to ND. We aim to evaluate if diabetes mellitus has an impact on TAVR outcome and remodeling patterns. Methods: All consecutive patients who underwent TAVR (2007-2012) were included in this analysis. A comparison of baseline, procedural, post-procedural outcomes and echocardiographic left-ventricle mass indices was performed between DM and ND patients. Results: DM was prevalent in 165 of 499 (33.0%) consecutive patients who underwent TAVR. DM patients were younger, weighed more, had higher rates of renal insufficiency and larger caliber peripheral vessels. Other than that, no disparities were noted in baseline characteristics. Procedural aspects were mostly similar between the groups but ND patients had higher rates of both vascular complications and bleeding. This did not translate into statistically significant differences in mortality both at 30. days and at 1. year (DM 6.7% vs. ND 10.5%; p=. 0.16 and DM 22.4% vs. 25.7%; p=. 0.48, respectively). Incidences of reverse remodeling patterns were similar between the two groups. Conclusion: TAVR outcome is probably driven by baseline characteristics and post-operative complications while diabetes itself is not associated with poor outcome after TAVR.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalIJC Metabolic and Endocrine
StatePublished - 1 Dec 2015
Externally publishedYes


FundersFunder number
Edwards Lifesciences
Medicines Company


    • Aortic stenosis
    • Diabetes mellitus
    • Transcatheter aortic valve replacement


    Dive into the research topics of 'The impact of diabetes mellitus on outcome of patients undergoing transcatheter aortic valve replacement'. Together they form a unique fingerprint.

    Cite this